RxDoctor Payments Data

Karishma Habbu, MD

Ophthalmology · Evansville, INNPI 1003341413

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.5% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.

$4,260in general payments, 2019–2025

Across 124 payments — averaging $34.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$543
  • Regeneron Healthcare Solutions, Inc.$380
  • Johnson & Johnson Surgical Vision, Inc.$315
  • Notal Vision, Inc.$306
  • AbbVie$305
  • Glaukos Corporation$269
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$3067%
  • Food & beverage$3,85490%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,260 in reported general payments places this provider in the 80th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$263,689
Medicare patients
515
Services billed
1,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine50$71,425
XiidraLifitegrast15$28,325
Cyclosporine13$5,329
Prednisolone Acetate126$4,028
Ketorolac Tromethamine88$3,038
ValacyclovirValacyclovir Hcl15$1,763
MoxifloxacinMoxifloxacin Hcl69$1,497
Latanoprost75$1,453
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$361
ErythromycinErythromycin Base30$232
Timolol Maleate19$158
Tobramycin23$116
Prednisone11$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$305$71,42550 claims
Bausch & Lomb Americas Inc.Xiidra$223$28,32515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →